Table 1 Summary of in vivo E2, IndCl, and IndCl analogue treatment effects compared to vehicle.
Category | Marker | Pre E2 | Post E2 | IndCl | IndCl-o-Cl | IndCl-o-Me |
|---|---|---|---|---|---|---|
Disability | Disease score§ | − | ° | °, - | − | − |
Rotarod performance§ | + | ° | ° | + | + | |
Myelination | OLs | + | + | + | + | + |
MBP | + | ° | + | + | + | |
g-ratio | − | ° | − | − | − | |
Peripheral Inflammatory Cytokines | IFNγ | − | − | − | − | − |
IL-1β§ | ° | ° | + | ° | ° | |
IL-2 | − | ° | ° | ° | ° | |
IL-6§ | − | − | ° | − | − | |
IL-17§ | − | − | ° | − | − | |
TNFα | ° | ° | ° | ° | ° | |
Peripheral Th2 & Anti-inflammatory Cytokines | IL-4 | ° | ° | ° | ° | ° |
IL-5 | ° | ° | ° | ° | ° | |
IL-10 | ° | ° | ° | ° | ° | |
IL-13§ | ° | ° | ° | − | − | |
Peripheral Chemokines | CXCL1 | + | + | + | + | + |
CXCL10 | − | − | − | − | − | |
CNS Chemokines | CXCL1 | ° | + | + | + | + |
CNS Cellular Inflammation | CD45 | − | − | − | − | − |
GFAP | − | ° | ° | ° | ° | |
Callosal CAP Electrophysiology | N1 amplitude | ° | ° | + | + | + |
N2 amplitude§,# | ° | ° | ° | + | ° |
